Evaluating the Impact and Performance of SeqOIA and AURAGEN Genomic Sequencing Platforms on Cancer Patient Care in France

What this Trial Is About

Researchers are studying how high-throughput genomic sequencing platforms, SeqOIA and AURAGEN, affect cancer patient care and treatment decisions. This observational study gathers clinical and organizational data to assess key factors such as the quality of patient information, turnaround times for results, and overall quality of care. The project supports public health decisions and helps plan future genomic medicine services in France. The study collects data from patients with cancer who are referred for genomic sequencing validated by a multidisciplinary tumor board since January 1, 2021. Clinical and molecular decisions come from national tumor boards documented via digital tools, while additional clinical data are taken from hospital medical records before and after sequencing. The study measures includes turnaround time for sequencing results and treatment recommendations following multidisciplinary meetings. Participants contribute through the collection of clinical data and tumor board reports, with key outcome measures including the time from sample arrival to analysis, time from sequencing to report signing, and time until treatment recommendations are made. The study monitors these indicators over periods of 8 weeks and 6 months to understand how genomic information affects care pathways. This research aims to optimize genomic workflows and guide national health strategies for cancer care.

Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients